Cancel

Analyst consensus

Check the latest analyst estimates by VARA Research

Jump to

Analyst consensus

A wide range of sell-side analysts provide coverage of dsm-firmenich for their clients and the broader market.

Sell-side analyst coverage
InstitutionAnalyst
ABN AMROStefano Toffano
Bank of America Merrill LynchMatthew Yates
BarclaysAlex Sloane
Berenberg BankSebastian Bray
CitigroupSebastian Satz
Davy ResearchCathal Kenny
Deutsche BankVirginie Boucher-Ferte
EquitaMassimo Bonisoli
Exane BNP ParibasNicola Tang
Goldman SachsGeorgina Fraser
INGReg Watson
JefferiesChris Counihan
JP MorganChetan Udeshi
KBC SecuritiesWim Hoste
Kepler ChevreuxMartin Rödiger
Morgan Stanley Lisa De Neve
MorningstarRob Hales
DeGroof PetercamFernand de Boer
Rothschild & Co RedburnArtem Chubarov
UBSCharles Eden
Van Lanschot Kempen Eric Wilmer

Disclaimer
Any opinions, forecasts, estimates, projections, or predictions regarding dsm-firmenich’s performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections, or predictions of dsm-firmenich or its management. By providing the names of the analysts, dsm-firmenich does not imply its endorsement of or concurrence with their reports, conclusions, or recommendations. dsm-firmenich assumes no liability for the accuracy of the information provided by analysts and undertakes no obligation to update this information.

Consensus figures per
July 3, 2025

The most recent consensus figures provided by Vara Research are detailed below. The figures are based on the estimates given by the banks that were approached.

 Q2 2024H1 2024FY 2024Q1 2025Q2 2025 EH1 2025 EFY 2025 E
        
dsm-firmenich, total sales (including temporary positive vitamin effect)       
  - Number of Estimates    131313
  - Highest    3,4686,74213,298
  - Consensus3,2276,29812,7993,2743,2396,51312,846
  - Median    3,2206,49412,892
  - Lowest    3,1376,41112,453
P&B, sales       
  - Number of Estimates    121211
  - Highest    1,0922,1074,122
  - Consensus1,0212,0073,9641,0151,0012,0173,974
  - Median    9962,0113,973
  - Lowest    9531,9683,852
TTH, sales       
  - Number of Estimates    121211
  - Highest    8621,7133,375
  - Consensus8341,6323,2458518281,6793,288
  - Median    8281,6793,285
  - Lowest    7881,6393,199
HNC, sales       
  - Number of Estimates    121211
  - Highest    5671,0952,196
  - Consensus5651,0912,2145285361,0642,148
  - Median    5341,0622,153
  - Lowest    5021,0302,029
ANH, sales       
  - Number of Estimates    121211
  - Highest    9201,7943,553
  - Consensus7901,5363,3248748591,7333,375
  - Median    8621,7363,326
  - Lowest    8021,6763,215
Corporate, sales       
  - Number of Estimates    121211
  - Highest    263274
  - Consensus1732526172350
  - Median    172351
  - Lowest    61224
        
dsm-firmenich, total organic sales growth in % (including temporary positive vitamin effect)       
  - Number of Estimates    111112
  - Highest    7.17.96.7
  - Consensus74685.96.75.4
  - Median    6.16.85.4
  - Lowest    4.53.24.1
P&B, organic sales growth in %       
  - Number of Estimates    101010
  - Highest    32.54.2
  - Consensus137721.31.52.9
  - Median    1.31.72.9
  - Lowest    -20.01.5
TTH, organic sales growth in %       
  - Number of Estimates    101010
  - Highest    6.16.56.3
  - Consensus118874.85.95.5
  - Median    4.85.95.4
  - Lowest    3.55.24.5
HNC, organic sales growth in %       
  - Number of Estimates    101010
  - Highest    77.27.1
  - Consensus1-4175.16.15.4
  - Median    5.36.15.5
  - Lowest    13.93.2
ANH, organic sales growth in %       
  - Number of Estimates    101010
  - Highest    18.218.613
  - Consensus2-151914.416.78.8
  - Median    15.517.28.3
  - Lowest    8.313.75.8
        
dsm-firmenich, total Adj. EBITDA (including temporary positive vitamin effect)       
  - Number of Estimates    131313
  - Highest    6171,2672,406
  - Consensus5139762,1186506091,2592,370
  - Median    6101,2602,376
  - Lowest    6001,2502,287
P&B, Adj. EBITDA       
  - Number of Estimates    121212
  - Highest    219449899
  - Consensus220454882230214444881
  - Median    215445884
  - Lowest    208438860
TTH, Adj. EBITDA       
  - Number of Estimates    121212
  - Highest    172340677
  - Consensus159309615168167335658
  - Median    167335659
  - Lowest    161329627
HNC, Adj. EBITDA       
  - Number of Estimates    121212
  - Highest    102194412
  - Consensus941733719298190400
  - Median    99191402
  - Lowest    86178384
ANH, Adj. EBITDA       
  - Number of Estimates    121212
  - Highest    164350581
  - Consensus6387343186152338533
  - Median    151337528
  - Lowest    147333503
Corporate, Adj. EBITDA       
  - Number of Estimates    121212
  - Highest    -18-44-80
  - Consensus-23-47-93-26-23-49-94
  - Median    -24-50-95
  - Lowest    -25-51-101
        
Core adj. EBIT       
  - Number of Estimates    0811
  - Highest    -9891,814
  - Consensus-5251,213--8051,468
  - Median    -8071,484
  - Lowest    -6111,073
Core adj. net profit       
  - Number of Estimates    0811
  - Highest    -7171,306
  - Consensus-365849--5731,046
  - Median    -5881,036
  - Lowest    -408829
Core adj. EPS       
  - Number of Estimates    0811
  - Highest    -2.654.82
  - Consensus-1.353.10--2.153.95
  - Median    -2.163.91
  - Lowest    -1.543.13
        
What is your expected FX effect in million EUR on total  EBITDA for Q2 and FY 2025?       
  - Number of Estimates    999
  - Highest    -15-15-30
  - Consensus   0-23-22-65
  - Median    -20-20-65
  - Lowest    -33-33-95

Disclaimer
Any opinions, forecasts, estimates, projections, or predictions regarding dsm-firmenich's performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections, or predictions of dsm-firmenich or its management. By providing the names of the analysts, dsm-firmenich does not imply its endorsement of or concurrence with their reports, conclusions, or recommendations. dsm-firmenich assumes no liability for the accuracy of the information provided by analysts and undertakes no obligation to update this information.

Contact Investor relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.

Get in touch
Explore more

  • Executive Committee

    The Executive Committee is organized and led by our CEO, who is responsible for overseeing the operational management of the Group.

    Read more

  • Sustainability

    Sustainability is fundamental to how dsm-firmenich brings progress to life – for people and planet.

    Read more